PROGRAM OBJECTIVE
The goal of the Medical Clinics of North America is to keep practicing physicians up to date with current clinical practice by providing timely articles reviewing the state of the art in patient care.

TARGET AUDIENCE
All practicing physicians and other healthcare professionals.

LEARNING OBJECTIVES
Upon completion of this activity, participants will be able to:
1. Review topical and biological therapies for diabetic foot ulcers as well as hyperbaric oxygen therapy as adjunctive treatment of diabetic foot ulcers.
2. Discuss peripheral arterial disease and bypass surgery in the diabetic lower limb.
3. Recognize, manage, and diagnose osteomyelitis in the diabetic foot.

ACCREDITATION
The Elsevier Office of Continuing Medical Education (EOCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The EOCME designates this enduring material for a maximum of 15 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other health care professionals requesting continuing education credit for this enduring material will be issued a certificate of participation.

DISCLOSURE OF CONFLICTS OF INTEREST
The EOCME assesses conflict of interest with its instructors, faculty, planners, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by EOCME for fair balance, scientific objectivity, and patient care recommendations. EOCME is committed to providing its learners with CME activities that promote improvements or quality in healthcare and not a specific proprietary business or a commercial interest.

The planning committee, staff, authors and editors listed below have identified no financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:
Mostafa A. Albayati, BSc, MBBS, DMCC; David G. Armstrong, DPM, MD, PhD; Andrew JM Boulton, MD, DSc (Hon), FACP, FRCP; Santha Priya Boorasamy; Javier La Fontaine, MS, DPM; Robert Frykberg, DPM, MPH; Frances L. Game, FRCP; Pamela Hetherington; Brynne Hunter; Adam L. Isaac, DPM; William Jeffcoate, MRCP; Edward B. Jude, MD; Paul J. Kim, MS, DPM; Sandy Lavery; Magnus Löndahl, MD, PhD; David J. Margolis, MD, PhD; Janice V. Mascarenhas, MBBS; Jill McNair; Lindsay Parnell; Jim A. Reekers, MD, PhD, EBIR; Nicholas A. Richmond, BS; Lee C. Rogers, DPM; Clifford P. Shearman, MS, FRCS; Wei Shen, MD, PhD; Alejandro C. Vivas, MD; Dane Wukich, MD.

The planning committee, staff, authors and editors listed below have identified financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interest related to the content of this CME activity:
Robert S. Kirsner, MD, PhD is a consultant/advisor for Organogenesis Inc. and Shire, and has a research grant from Healthpoint.
Lawrence A. Lavery, MPH, DPM is on speakers bureau for Innovative Therapies Inc., Pamlab, Inc., KCI Licensing, Inc. and Shire Regenerative Medicine; is consultant advisor for Innovative Therapies Inc., Pamlab, Inc. and KCI Licensing, Inc.; has stock ownership in Diabetica Solutions Inc. and Prizm Medical Inc.; has research grants from Osiris Therapeutics Inc, Thermotek, MacroCure, GlaxoSmithKline, Innovative Therapies Inc, Pamlab, Inc. and KCI Licensing, Inc.; and has royalties/patents with Diabetica Solutions.
Benjamin A. Lipsky, MD, FACP, FIDSA, FRCP is on speakers bureau for Merck & Co., Inc. and Novartis Pharmaceuticals Corporation; is a consultant/advisor for Innocoll, Cerexa, Inc. and Novartis Pharmaceuticals Corporation; and has a research grant from Innocoll.
Edgar J.G. Peters, MD, PhD has a research grant from Fonds Nuts Ohra.

UNAPPROVED/OFF-LABEL USE DISCLOSURE
The EOCME requires CME faculty to disclose to the participants:
1. When products or procedures being discussed are off-label, unlabelled, experimental, and/or investigational (not US Food and Drug Administration (FDA) approved); and
2. Any limitations on the information presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinions. Faculty may discuss information about pharmaceutical agents that is outside of FDA-approved labelling. This information is intended solely for CME and is not intended to promote off-label use of these medications. If you have any questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

TO ENROLL
To enroll in the Medical Clinics of North America Continuing Medical Education program, call customer service at 1-800-654-2452 or sign up online at http://www.theclinics.com/home/cme. The CME program is available to subscribers for an additional annual fee of USD $267.

METHOD OF PARTICIPATION
In order to claim credit, participants must complete the following:
1. Complete enrolment as indicated above.
2. Read the activity.
3. Complete the CME Test and Evaluation. Participants must achieve a score of 70% on the test. All CME Tests and Evaluations must be completed online.

CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com